

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/809,483	03/15/2001	Kurt R. Linberg	P-8945	5644
27581 7	590 08/01/2006		EXAMINER	
MEDTRONIC, INC.			NAJARIAN, LENA	
710 MEDTRONIC PARK MINNEAPOLIS, MN 55432-9924			ART UNIT	PAPER NUMBER
	•		3626	
			DATE MAILED: 08/01/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	09/809,483	LINBERG ET AL.	
Office Action Summary	Examiner	Art Unit	
	Lena Najarian	3626	
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet w	ith the correspondence addre	ess
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perion. - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNI 1.136(a). In no event, however, may a od will apply and will expire SIX (6) MOI tute, cause the application to become A	CATION. reply be timely filed NTHS from the mailing date of this comr BANDONED (35 U.S.C. § 133).	
Status			
1)⊠ Responsive to communication(s) filed on 29 2a)⊠ This action is FINAL . 2b)□ The 3)□ Since this application is in condition for allow closed in accordance with the practice under the condition of the	his action is non-final. vance except for formal mat	· ·	nerits is
Disposition of Claims			
4) Claim(s) 22-29 is/are pending in the applicate 4a) Of the above claim(s) is/are withd 5) Claim(s) is/are allowed. 6) Claim(s) 22-29 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and Application Papers	rawn from consideration.		
9) The specification is objected to by the Exami 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the	ccepted or b) objected to ne drawing(s) be held in abeya ection is required if the drawing	nce. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR	
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreignal All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume * See the attached detailed Office action for a literal 	ents have been received. ents have been received in A riority documents have beer eau (PCT Rule 17.2(a)).	Application No received in this National St	age
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date	Paper No	Summary (PTO-413) (s)/Mail Date Informal Patent Application (PTO-1) 	52)

Application/Control Number: 09/809,483 Page 2

Art Unit: 3626

DETAILED ACTION

Notice to Applicant

1. This communication is in response to the amendment filed 6/29/06. Claims 22-29 remain pending. Claim 22 has been amended.

Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 22-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Elkind (US 2003/0158754 A1) in view of Linder et al. (US 6,681,003 B2), in view of Segal et al. (US 2001/0041991 A1), and further in view of Ilsen et al. (US 6,757,898 B1).
- (A) Referring to claim 22, Elkind discloses a data communications server system, comprising (see abstract of Elkind):

an information network (abstract of Elkind);

means for logging into the information network (para. 12 of Elkind);

a communications portal resident on a server and accessed over an information network to present information associated with a patient, comprising (Fig. 3 and Fig. 4 of Elkind):

Application/Control Number: 09/809,483

Art Unit: 3626

means for allowing a user to log-in to the communications portal (para. 12 of Elkind);

means for making a user verification (para. 12 of Elkind);
means for automatically presenting a web page (Fig. 7 of Elkind);
means for accessing a patient medical records database over the
information network (para. 2 of Elkind); and

means for integrating accessible databases through user selectable links (Fig. 7 of Elkind).

Elkind discloses data relating to medical devices, such as pacemakers or other implants (see para. 44 of Elkind). However, Elkind does not expressly disclose an individual implantable medical device patient and an implantable medical device database.

Linder discloses an individual implantable medical device patient and an implantable medical device database (see col. 9, lines 33-41 and col. 3, lines 5-13 of Linder).

Elkind and Linder do not expressly disclose a patient lab records database.

Segal discloses a patient lab records database (para. 112 and Fig. 1 of Segal).

Elkind, Linder, and Segal do not expressly disclose that the web page is customized to the individual implantable medical device patient that includes a display of information relevant to the implantable medical device implanted in the patient.

Ilsen discloses that the web page is customized to the patient and includes a display of information relevant to the patient (col. 33, lines 20-24 of Ilsen).

Application/Control Number: 09/809,483

Art Unit: 3626

At the time of the invention, it would have been obvious to a person of ordinary skill in the art to combine the aforementioned features of Linder, Segal, and Ilsen within Elkind. The motivation for doing so would have been to monitor and upgrade the performance of the device (col. 3, lines 5-13 of Linder), to track results of tests and procedures (para. 112 of Segal), and to provide a fully automated mechanism for generating a personalized area (col. 4, lines 41-43 of Ilsen).

Page 4

(B) Claims 23-29 have not been amended and are rejected for the same reasons given in the previous Office Action, and incorporated herein.

Response to Arguments

- 4. Applicant's arguments with respect to claim 22 have been considered but are moot in view of the new ground(s) of rejection.
- 5. Applicant's arguments filed 6/29/06 have been fully considered but they are not persuasive. Applicant's arguments will be addressed hereinbelow in the order in which they appear in the response filed 6/29/06.
- (1) Applicant argues at page 5 that Ilsen does not disclose a "customized" web page and that the abstract merely mentions that the system generates a personalized area (patient page) for each user.
- (2) Applicant argues at pages 5-6 that Linder et al. does not concern an implantable medical device and that there is no similarity in the objections of Elkind and Linder that would promote even attempting to combine the features of the two references.

Art Unit: 3626

(A) As per the first argument, the Examiner fails to understand the distinction between a patient being able to view his/her *customized* content over a secure Internet connection (see col. 33, lines 20-24 of Ilsen) disclosed by Ilsen and the "customized" web page claimed by Applicant.

(B) As per the second argument, the Examiner respectfully disagrees that Linder et al. does not concern an implantable medical device. At lines 2-6 of Linder's abstract, it is disclosed that "a medical device, such as a portable or implantable medical device, collects patient and operational information...." Also note col. 9, lines 33-41 of Linder.

In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, the Examiner cited motivations to combine directly from the references.

Conclusion

6. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The cited but not applied prior art teaches an online system and method for providing composite entertainment and health information (5,951,300) and a

Page 6

Art Unit: 3626

Application/Control Number: 09/809,483

method, apparatus and system for providing targeted information in relation to laboratory and other medical services (US 2002/0007285 A1).

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lena Najarian whose telephone number is 571-272-7072. The examiner can normally be reached on Monday - Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Thomas can be reached on 571-272-6776. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/809,483 Page 7

Art Unit: 3626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.